Myriad Genetics, Inc., has announced results from PROCEDE 500, a clinical utility study with its Prolaris prognostic test, at last week’s 2014 ASCO Genitourinary Cancers Symposium. According to company representatives, the study demonstrates the significant clinical value of Prolaris for physicians who are treating men with prostate cancer. Prolaris, which predicts prostate cancer-specific death and metastases, has been validated in 11 clinical studies with more than 5,000 patients.
PROCEDE 500 is an ongoing prospective registry study designed to examine the clinical utility of Prolaris. Currently, 331 patients have been enrolled and 150 clinicians have completed surveys in 305 cases to assess the influence of the Prolaris score on clinical decision making. Results for these interim data show that in 65% of cases, physicians changed their intended therapy and selected a different treatment based on the Prolaris test score. In 40% of patients, physicians reduced the therapeutic burden on patients and opted for conservative management options such as active surveillance and watchful waiting. In 25% of cases, physicians increased treatments, including the use of surgery or radiation, and in 35% of cases, physicians did not change their treatment plans. Full results from PROCEDE 500 have been submitted to a peer-reviewed medical journal for publication. Learn more about the Prolaris test.